Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City

Microbial Drug Resistance

Volumn 24, Issue 1, 2018, Pages 35-39

  Manning, Nyla ^a   Balabanian, Gregory ^a   Rose, Michael ^a   Landman, David ^a   Quale, John ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

carbapenemase; ceftazidime avibactam; Klebsiella pneumoniae

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEMASE; POLYMYXIN B; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA-LACTAMASE KPC-2, KLEBSIELLA PNEUMONIAE; BETA-LACTAMASE KPC-3, KLEBSIELLA PNEUMONIAE; CEFTAZIDIME; OMPK35 PORIN, KLEBSIELLA PNEUMONIAE; PORIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG POTENTIATION; FRAMESHIFT MUTATION; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; NEW YORK; NONHUMAN; PRIORITY JOURNAL; DRUG COMBINATION; DRUG EFFECT; ENDEMIC DISEASE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

AMIKACIN; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; DRUG COMBINATIONS; DRUG SYNERGISM; ENDEMIC DISEASES; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MUTATION; NEW YORK CITY; POLYMYXIN B; PORINS;

EID: 85040604044     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2016.0293     Document Type: Article

References (17)

1. Sylvia Munoz-Price, L., L. Poirel, R.A. Bonomo, M.J. Schwaber, G.L. Daikos, M. Cormican, G. Cornaglia, J. Garau, M. Gniadkowski, M.K. Hayden, K. Kumarasamy, D.M. Livermore, J.J. Maya, P. Nordmann, J.B. Patel, D.L. Paterson, J. Pitout, M.V. Villegas, H. Wang, N. Woodford, J.P. Quinn. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect. Dis. 13:785-796.
2. Falagas, M.E., P. Lourida, P. Poulikakos, P.I. Rafailidis, G.S. Tansarli. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: Systematic evaluation of the available evidence. Antimicrob. Agents Chemother. 58:654-663.
3. Drawz, S.M., K.M. Papp-Wallace, R.A. Bonomo. 2014. New b-lactamase inhibitors: A therapeutic renaissance in an MDR world. Antimicrob. Agents Chemother. 58:1835-1846.
4. Sader, H.S., M. Castanheira, R.K. Flamm, D.J. Farrell, R.N. Jones. 2014. Antimicrobial activity of ceftazidimeavibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob. Agents Chemother. 58:1684-1692.
5. Papp-Wallace, K.M., M. Winkler, M.A. Taracila, R.A. Bonomo. 2015. Variants of b-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob. Agents Chemother. 59:3710-3717.
6. Livermore, D.M., M. Warner, D. Jamrozy, S. Mushtaq, W.W. Nichols, N. Mustafa, N. Woodford. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob. Agents Chemother. 59:5324-5330.
7. Humphries, R.M., S. Yang, P. Hemarajata, K.W. Ward, J.A. Hindler, S.A. Miller, A. Gregson. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob. Agents Chemother. 59:6605-6607.
8. Shields, R.K., B.A. Potoski, G. Haidar, B. Hao, Y. Doi, L. Chen, E.G. Press, B.N. Kreiswirth, C.J. ClancyJ, M.H. Nguyen. 2016. Clinical outcomes, drug toxicity, emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin. Infect. Dis. 63(12): 1615-1618.
9. Abdallah, M., O. Olafisoye, C. Cortes, C. Urban, D. Landman, M. Ghitan, B. Collins, S. Bratu, J. Quale. 2016. The rise and fall of KPC-producing Klebsiella pneumoniae in New York City. J. Antimicrob. Chemother. 71:2945-2948.
10. Clinical and Laboratory Standards Institute. 2014. Performance Standards for Antimicrobial Susceptibility Testing. Approved standard M100-S24. Twenty-fourth Informational Supplement. Clinical Laboratory Standards Institute, Wayne, PA.
11. Landman, D., S. Bratu, J. Quale. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J. Med. Microbiol. 58:1303-1308.
12. Landman, D., E. Babu, N. Shah, P. Kelly, O. Olawole, M. Backer, S. Bratu, J. Quale. 2012. Transmission of carbapenem-resistant pathogens in New York city hospitals: Progress and frustration. J. Antimicrob. Chemother. 67:1427-1431.
13. Landman, D., N. Mobarakai, J.M. Quale. 1993. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, gentamicin. Antimicrob. Agents Chemother. 37;1904-1908.
14. Bratu S., M. Mooty, S. Nichani, D. Landman, C. Gullans, B. Pettinato, U. Karumudi, P. Tolaney, J. Quale. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020.
15. Shields, R.K., C.J. Clancy, B. Hao, L. Chen, E.G. Press, N.M. Iovine, B.N. Kreiswirth, M.H. Nguyen. 2015. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum b-lactamases, porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob. Agents Chemother. 59;5793-5797.
16. Pages, J.M., S. Peslier, T.A. Keating, J.P. Lavigne, W.W. Nichols. 2016. Role of the outer membrane and porins in susceptibility of b-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob. Agents Chemother. 60:1349-1359.
17. Domenech-Sanchez, A., L. Martinez-Martinez, S. Hernandez-Alles, M. del Carmen Conejo, A. Pascual, J.M. Tomas, S. Alberti, V.J. Benedi. 2003. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob. Agents Chemother. 47:3332-3335.